
Pharmaceutical in-licensing for the U.S. and Canadian market.
Visit Global PharmaPartnersBiopharmaceutical Company · Biologics & Peptides
BioFutureRx advances a deep biologics portfolio — biosimilars, first-in-class antibodies, diagnostics, and delivery platforms — through a strategic development partnership, alongside its own in-house peptide program led by BFRx3711, a novel long-acting GLP-1.
A Biopharmaceutical Company
BioFutureRx is a biopharmaceutical company focused on biologic medicines. Through a strategic development and manufacturing partnership, we advance a broad portfolio of biosimilars, first-in-class antibodies, diagnostics, and delivery platforms — and we engineer our own peptide therapeutics in-house, led by BFRx3711.
Why BioFutureRx
Biosimilars, first-in-class and novel antibodies, diagnostics, and delivery platforms — a multi-dimensional portfolio advanced through a strategic development partnership.
Novel-target antibody discovery and humanization, led by a clinical-stage candidate in pancreatic cancer, across oncology, immunology, and infectious disease.
BFRx3711, a proprietary in-house GLP-1 analog engineered for potential once-monthly dosing — our own asset alongside the biologics portfolio.
Biologics
Biosimilars, novel and first-in-class antibodies, companion diagnostics, and drug-delivery platforms — shown by molecule, indication, and stage.
Learn morePeptides
BFRx3711, our proprietary long-acting GLP-1 analog engineered in-house for potential once-monthly dosing in obesity and type 2 diabetes.
Learn moreOur Network
BioFutureRx works alongside sister companies across pharmaceutical licensing, capital, and marketplace — explore the wider network.

Pharmaceutical in-licensing for the U.S. and Canadian market.
Visit Global PharmaPartners
Investment and financing partner — smart strategies for a complex world.
Visit Intelligentzia Capital Management
The marketplace for inactive and discontinued ANDAs.
Visit ANDA Exchange